A letter from the Assistant Secretary for Legislation, Department of Health and Human Services, transmitting the Department's fiscal year 2025 Report on Understanding the Long-Term Health Effects of Living Organ Donation; to the Committee on Energy and Commerce.
A letter from the Director, Office of Congressional Affairs, Nuclear Regulatory Commission, transmitting the Commission's direct final rule and issuance of environmental assessment - AP1000 Design Certification Renewal [NRC-2026-2377] (RIN: 3150-AL70) received October 21, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Supervisory, Program Analyst, Media Bureau, Federal Communications Commission, transmitting the Commission's final rule - Amendment of section 73.202(b) Table of Allotments, FM Broadcast Stations (Whitehall, Michigan) [MB Docket No.: 26-152] received October 26, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Deputy Chief, Space Bureau, Federal Communications Commission, transmitting the Commission's final rule - Satellite Spectrum Abundance [SB Docket No. 25-180]; Spectrum Abundance for Weird Space Stuff [SB Docket No. 26-54]; Expanding Use of the 12.7-13.25 GHz Band for Mobile Broadband or Other Expanded Use [GN Docket No. 22-352 (Terminated)]; Shared Use of the 42-42.5 GHz Band [WT Docket No. 23-158 (Terminated)]; Use of Spectrum Bands Above 24 GHz for Mobile Radio Services [GN Docket No. 14-177] received October 19, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Attorney Advisory, Policy Division, Consumer and Governmental Affairs Bureau, Federal Communications Commission, transmitting the Commission's final rule - Rules and Regulations Implementing the Telephone Consumer Protection Act of 1991 [CG Docket No. 02-278] received October 19, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Associate Administrator for Congressional and Intergovernmental Relations, Environmental Protection Agency, transmitting a report titled, "FY 2025 Superfund Five-Year Review Report to Congress", pursuant to section 121(c) of the Comprehensive Environmental Response, Compensation and Liability Act; to the Committee on Energy and Commerce.
A letter from the Acting Branch Chief, Regulatory Management Branch, Environmental Protection Agency, transmitting the Agency's final rule - Approval and Promulgation of Implementation Plans; Arizona; Revisions to the Cleaner Burning Gasoline, Winter Oxygenated Fuel, and Gasoline Set-Aside Programs [EPA-R09-OAR-2023-0054; FRL-12607-02-R9] received October 19, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting the Department's notice of proposed rulemaking - Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products [Docket No.: DEA-1664] (RIN: 1117-ZA08) received September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting the Department's final rule - Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act [Docket No.: DEA-989] received September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Deputy Assistant Administrator, Diversion Control Division, Drug Enforcement Administration, Department of Justice, transmitting the Department's final rule - Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment [Docket No.: DEA-499] (RIN: 1117-AB55) September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting the Department's final rule - Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments [Docket No.: DEA-1005] received September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting the Department's final rule - Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I [Docket No.: DEA-1146] received September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting the Department's final rule - Schedules of Controlled Substances: Placement of Diphenidine in Schedule I [Docket No.: DEA1155] received September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting the Department's final rule - Designation of Propionyl Chloride as a List I Chemical [Docket No.: DEA-1189] received September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
The SPEAKER presented a memorial of the Legislature of the State of Louisiana, relative to House Resolution No. 324, to urge and request certain entities and medical, public health, coding, and classification authorities to review and revise medical terminology relating to miscarriage and pregnancy loss to ensure that such terminology is medically accurate, patient-centered, compassionate and sensitive to women and families experiencing the loss of an unborn child.; to the Committee on Energy and Commerce.
A letter from the Acting Branch Chief, Regulatory Management Branch, Environmental Protection Agency, transmitting the Agency's final rule - Phosphatidylcholine in Pesticide Formulations; Exemption from the Requirement for a Tolerance [EPA-HQ-OPP-2025-0090; FRL-13583-01-OCSPP] received October 1, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Acting Branch Chief, Regulatory Management Branch, Environmental Protection Agency, transmitting the Agency's final rule - Air Plan Approval; Missouri; Control of NOx Emissions From Large Stationary Internal Combustion Engines [EPA-R07-OAR-2026-4819; FRL-13460-02-R7] received October 1, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Acting Branch Chief, Regulatory Management Branch, Environmental Protection Agency, transmitting the Agency's final rule - Attainment Date Extension for the South Coast, California 2012 Annual PM2.5 Fine Particulate Matter Nonattainment Area [EPA-R09-OAR-2026-3664; FRL-13379-02-R9] received October 1, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting the Department's proposed amendment - Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I [Docket No.: DEA-1641] received September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Deputy Assistant Administrator, Drug Enforcement Administration, Department of Justice, transmitting the Department's proposed amendment - Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I [Docket No.: DEA-1644] received September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Deputy Assistant Administrator, Drug Enforcement Administration, Department of Justice, transmitting the Department's temporary amendment - Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I [Docket No.: DEA-1644] received September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting the Department's notice of proposed rulemaking - Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V [Docket No.: DEA-1645] received September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting the Department's proposed amendment - Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act [Docket No.: DEA-1665] received September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting the Department's notice of proposed rulemaking - Revision of Applications for Manufacturing and Procurement Quotas [Docket No.: DEA-1278] (RIN: 1117-AB86) received September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.
A letter from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting the Department's notice of proposed rulemaking - Designation of Phenethyl Halides as List I Chemicals [Docket No.: DEA-1282] received September 23, 2026, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104–121, section 251; (110 Stat. 868); to the Committee on Energy and Commerce.